Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
280 participants
OBSERVATIONAL
2013-04-30
2014-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Community-based Microalbuminuria Screening in Patients With Hypertension
NCT03596840
Preventing Microalbuminuria in Type 2 Diabetes
NCT00503152
Risk Factors Contributing to the Development of Microalbuminuria
NCT00572403
Rationale and Design for Shiga Microalbuminuria Reduction Trial
NCT00202618
Empagliflozin in Acute Heart Failure
NCT05305495
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* T2D patients with ongoing anti-diabetic therapy for at least 5 years
* Uncontrolled hypertension according to 2012 CHEP recommendations for management of hypertension in diabetic patients ( i.e. BP\> 130/80 mmHg)
* Able and agreeing to provide informed consent.
Exclusion Criteria
* Ongoing therapy with perindopril,
* Known hypersensitivity or allergies to ACEI or sulfonamide derivatives,
* A history of angioedema related or not to previous treatment with ACEI,
* Impaired renal function defined as serum creatinine levels \> 177 µmol/L, eGFR \<30 mL/min,
* Hyperkalemia or hypokalemia,
* Severe hepatic impairment,
* Use of non-antiarrhythmic agents causing torsade de pointes,
* Pregnant or lactating women, or who are planning to become pregnant,
* Any conditions which may impact on participation according to treating physician.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Medpharmgene, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Medpharmgene
Montreal, Quebec, Canada
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CLINPRADIA
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.